-- Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has received five observations from the US FDA concluded an inspection at our manufacturing facility at Paithan in Maharashtra, India, according to a filing to the Indian stock exchanges.
The regulator inspected the facility from April 13 to 21 and closed with the issuance of Form-483 with five observations.
The company said it will respond to the U.S. FDA within the stipulated timeline.
The company's shares were down nearly 1% in recent trade.